{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004578","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.242955+00:00","generated_at":"2026-05-28T03:26:10.915868+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Treace Medical preliminary Q4 rev ~$68.6M, FY2024 ~$209.2M, up 12% YoY","bullets":["Preliminary Q4 revenue $68.4M-$68.8M, ~10% increase at midpoint vs Q4 2023.","Full-year 2024 revenue $209.0M-$209.4M, ~12% growth at midpoint, in line with $204M-$211M guidance.","Added ~280 active surgeons in 2024; total ~3,135 active surgeons (+10% YoY), ~31% of US bunion surgeon market.","2025 financial guidance to be provided during Q4 2024 earnings call on Feb 27, 2025.","Management to present at J.P. Morgan Healthcare Conference on Jan 14, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004578","json":"https://secwatch.observer/filing/0000950170-25-004578.json","markdown":"https://secwatch.observer/filing/0000950170-25-004578.md","text":"https://secwatch.observer/filing/0000950170-25-004578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025004578/0000950170-25-004578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025004578/tmci-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:26:10.915868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}